Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by StockHawk1on Nov 03, 2022 5:19pm

130 Views

Post# 35071113

AGN files for Orphan Designation for Ifenprodil on IPF

Algernon Pharmaceuticals (AGN.c AGNPF) recently advanced its investigation of Ifenprodil for the treatment of the chronic lung condition IPF by filing a request to the FDA for Orphan Designation for this use of the drug.

AGN's recent Ifenprodil study found it lessened the frequency of patients' IPF-associated cough, so there is a solid basis to believe this drug could be commercialized for the treatment of IPF.

IMO receiving this Orphan Designation could be an upcoming catalyst for AGN to look out for

AGN @ $2.54, MC $6.034M

https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-files-orphan-designation-110000532.html

<< Previous

Bullboard Posts

Next >>

How to trade on the stock market: A beginner’s guide